Ítem
Solo Metadatos

Progress towards precision medicine for lupus: The role of genetic biomarkers

Mostrar el registro sencillo de la publicación
dc.creatorAnaya, Juan-Manuelspa
dc.creatorLeon K.J.spa
dc.creatorRojas M.spa
dc.creatorRodriguez Y.spa
dc.creatorPacheco Y.spa
dc.creatorAcosta Ampudia, Yeny Yasbleidyspa
dc.creatorMonsalve Carmona, Diana Marcelaspa
dc.creatorRamírez Santana, Heily Carolinaspa
dc.date.accessioned2020-05-26T00:08:00Z
dc.date.available2020-05-26T00:08:00Z
dc.date.created2018spa
dc.description.abstractSystemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disease (AD). Precision medicine gives clinicians and society access to the information needed to create individually tailored programs to predict, prevent, and treat SLE. Although several biomarkers have been described for SLE, current expansion of knowledge on lupus genetics makes the implementation of genetic biomarkers possible. Herein, a comprehensive description of relevant SLE genetic biomarkers from the precision medicine perspective is offered. National inception cohorts should be created and the implementation of translational programs for the control of ADs such as SLE should be put into practice. Factors that are predictive of developing these conditions should be examined at the population level in order to establish preventive measures in at-risk individuals for whom healthcare should be personalized/precise and participatory. The implementation of such a program will allow the discovery of new mechanisms and a new taxonomy of ADs. The translational model should also involve educational and training programs together with digital participatory surveillance systems. Healthcare’s one-size-fits-all approach to treating patients will be replaced with a personalized/precision approach to medicine that focuses on individuals and each family member. © 2018 Informa UK Limited, trading as Taylor and Francis Group.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1080/23808993.2018.1448266
dc.identifier.issn23808993
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/24047
dc.language.isoengspa
dc.publisherTaylor and Francis Ltd.spa
dc.relation.citationEndPage135
dc.relation.citationIssueNo. 2
dc.relation.citationStartPage119
dc.relation.citationTitleExpert Review of Precision Medicine and Drug Development
dc.relation.citationVolumeVol. 3
dc.relation.ispartofExpert Review of Precision Medicine and Drug Development, ISSN:23808993, Vol.3, No.2 (2018); pp. 119-135spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85053369428&doi=10.1080%2f23808993.2018.1448266&partnerID=40&md5=86bf23e49b695b9c3c1a1f64a1a7b14dspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordBiomarkersspa
dc.subject.keywordGeneticsspa
dc.subject.keywordPrecision medicinespa
dc.subject.keywordSubphenotypespa
dc.subject.keywordSystemic lupus erythematosusspa
dc.subject.keywordTranslational medicinespa
dc.titleProgress towards precision medicine for lupus: The role of genetic biomarkersspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos